Intercure Ltd INCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INCR is a good fit for your portfolio.
News
-
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
-
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million
-
Thinking about buying stock in Braze, Velo3D, InterCure, Equillium, or Bioatla?
-
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
Trading Information
- Previous Close Price
- $3.32
- Day Range
- $3.18–3.34
- 52-Week Range
- $0.99–3.72
- Bid/Ask
- $3.25 / $4.20
- Market Cap
- $149.93 Mil
- Volume/Avg
- 43,448 / 72,131
Key Statistics
- Price/Earnings (Normalized)
- 17.33
- Price/Sales
- 1.58
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 280
- Website
- https://www.intercure.co
Comparables
Valuation
Metric
|
INCR
|
EMDV
|
GNRS
|
---|---|---|---|
Price/Earnings (Normalized) | 17.33 | 6.91 | 2.84 |
Price/Book Value | 1.26 | 0.87 | 0.38 |
Price/Sales | 1.58 | 0.31 | 6.44 |
Price/Cash Flow | 33.70 | 3.51 | 17.84 |
Price/Earnings
INCR
EMDV
GNRS
Financial Strength
Metric
|
INCR
|
EMDV
|
GNRS
|
---|---|---|---|
Quick Ratio | 1.20 | 1.15 | 1.05 |
Current Ratio | 1.85 | 1.62 | 1.05 |
Interest Coverage | −1.75 | 2.18 | 3.34 |
Quick Ratio
INCR
EMDV
GNRS
Profitability
Metric
|
INCR
|
EMDV
|
GNRS
|
---|---|---|---|
Return on Assets (Normalized) | 0.87% | 3.82% | 7.30% |
Return on Equity (Normalized) | 1.53% | 14.05% | 14.19% |
Return on Invested Capital (Normalized) | 3.10% | 6.29% | 9.59% |
Return on Assets
INCR
EMDV
GNRS
Drug Manufacturers - Specialty & Generic Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Mzphjpzgc | Yjjn | $76.9 Bil | |
MKKGY
| Merck KGaA ADR | Rxjzwysqy | Spvyrv | $72.0 Bil | |
HLN
| Haleon PLC ADR | Qvvbrjnbl | Mxxbp | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Mvsgdqxtd | Yvwf | $17.8 Bil | |
VTRS
| Viatris Inc | Kdbyzcphf | Czjm | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Cxjvnfj | Bfqw | $12.5 Bil | |
CTLT
| Catalent Inc | Dntrgszx | Wbyml | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Bnxkmkzfg | Tvydt | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Tvjsjdyn | Schg | $3.9 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Kwsgxmzqw | Ytlqcrn | $3.5 Bil |